A £2.68 million study to investigate the effective use of antibiotics to treat certain types of severe asthma is being spearheaded by researchers in Leicester.
The project, which is chiefly funded by a partnership between the National Institute for Health Research (NIHR) and Medical Research Council (MRC), is part designed by asthma patients working with Asthma UK.
It is estimated that around 1 in 20 people with asthma have severe asthma. This typically presents as a high number of symptoms and poor lung function - despite regular medications - and repeated asthma attacks that frequently require time off work and admission to hospital.
Severe asthma is an umbrella term for several different disease types, which can be identified using blood tests (biomarkers). Many patients with severe asthma find that regular oral steroids have multiple intolerable side effects, including difficulty sleeping, weight gain, changes in mood, diabetes, weakening of the bones, high blood pressure and eye conditions such as glaucoma and cataracts, and wish to stop taking oral steroids as early as possible.
Chief Investigator for the study, Professor Salman Siddiqui, is a Professor of Airway Diseases at the University of Leicester and Consultant Respiratory Physician at Leicester's Hospitals. He said: "In this study we will work with severe asthma specialist centres in the UK to identify patients who experience frequent asthma attacks, which we define as two or more per year.
"We will then take a blood test that measures blood eosinophil level (a type of blood cell associated with inflammation) to identify two important subtypes of severe asthma. The first subtype of interest to us is called "T2-HIGH" severe asthma and might be driven by high numbers of eosinophils in the blood that then move to the airways in the lungs and may cause asthma attacks. The second subtype is called "T2-LOW" severe asthma and might be caused by bacteria living in the lungs and how they work with the immune cells. Depending on which type of severe asthma patients have, they will be split into two arms of the study."
Professor Dominick Shaw is a Professor of Respiratory Medicine at the University of Nottingham, Honorary Consultant at Nottingham University Hospitals NHS Trust and the T2-LOW trial national co-ordinator. He said: "Once we have identified patients in the T2-LOW subtype group we will test whether a simple, once daily oral antibiotic called doxycycline can reduce asthma attacks by changing the bacteria present in the lungs. This work will help to identify the right patients to give "long-term" antibiotics to, and to see whether the bacteria that live in the lungs might be responsible for causing asthma attacks in people with T2-LOW severe asthma.
"Knowing which patients are the right ones to receive antibiotics is important, as bacterial resistance to antibiotics through inappropriate use is a recognised global problem. Also, if we find out that targeting certain bacteria that live in the lung reduces asthma attacks, this could pave the way for future trials evaluating other types of intervention, such as probiotics."
Professor Siddiqui added: "The patients in the T2-HIGH subtype will test a new oral tablet called dexpramipexole, which lowers the number of eosinophils in the blood by stopping them growing in the person's bone marrow (the part of the body that produces new blood cells). We want to see if this treatment will be effective in reducing asthma attacks in patients with the T2-HIGH subtype of severe asthma. This work has the potential to provide an alternative option to oral steroids or biologic injections for this patient group."
The national charity, Asthma UK, has led patient involvement in the development and design of the trial and will continue to include patients with severe asthma for the duration of the study, with the support of patient representative, Val Hudson. Two national workshops were held to ensure the patients' voices were heard in the development of the grant. Asthma UK, which funds research into asthma and provides a nurse helpline to people with asthma, also consulted with the European asthma community, who all agreed this is valuable research.
Mrs Hudson said: "When you are involved as a patient in a clinical trial, both as a member of a patient input platform or as a trial participant, you are aware that you are not likely to personally benefit from the trial results but you hope that you will make a difference to people in the future with severe asthma.
"For me personally this trial is important because I am on very large doses of corticosteroids but they still do not stop me having asthma attacks, which are becoming more frequent, and require more oral steroids in response. Oral steroids are 'life savers' in emergency situations but in themselves can cause as many problems as they solve - like osteoporosis.
"A major issue with current asthma treatment is that it tries to tackle everything because no one has detected the type of severe asthma a person may have. This is what is so exciting about this trial; to discover the exact type of severe asthma and target treatment accordingly. It would be so much simpler if someone like me had treatment based on the exact cause and was able to respond to a small dose of antibiotics or a biological treatment that reduced the number of asthma attacks and thus the need for oral steroids."
Dr Samantha Walker, Director of Research and Policy at Asthma UK, and a co-applicant for the study, said: "We are really excited to be involved in this ground-breaking study which has the potential to identify new treatments for thousands of people suffering from severe asthma.
"This debilitating form of asthma is often resistant to regular treatments leaving people to deal with terrifying asthma attacks, repeated trips to A&E and often admission to hospital. Many people with severe asthma are currently dependent on long-term, high-dose oral steroids, which can cause toxic side effects such as diabetes or osteoporosis as well as sleep disturbance, weight gain and cataracts.
"Asthma UK has over 15 years' experience in involving people with asthma in research which has helped shape and drive the design and delivery of studies. It is vital that people with asthma are involved at all stages of research as they provide invaluable insight into their experiences and ensure that studies have the biggest possible impact."
The trial includes industry partners Knopp Biosciences and AstraZeneca. It is hosted by the Leicester Clinical Trials Unit and sponsored by the University of Leicester.
Professor Gavin Murphy, Head of the Leicester Clinical Trials Unit, said: "We at the Leicester CTU are delighted to be working with Salman and his collaborators on this landmark trial that will provide new and important knowledge that should improve the lives of patients with severe asthma."
The Efficacy and Mechanism Evaluation programme is an MRC and NIHR partnership created to support the evaluation of interventions with potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care.
###